REGISTER
Prof. Barata Discusses 177Lu-rosopatamab Safety Data in mCRPC
MedJ sat down with Prof. Pedro Barata to discuss the Phase III ProstACT Global trial, covering the mechanism of 177Lu-rosopatamab tetraxetan, key safety and dosimetry data, and its emerging role in mCRPC management.

Prof. Pedro Barata, MD, is a Medical Oncologist specializing in Genitourinary Oncology at University Hospitals Seidman Cancer Center. He serves as Associate Professor of Medicine at Case Western Reserve University School of Medicine, Director of the Genitourinary Medical Oncology Clinical Research Program, and a Member of the Molecular Oncology Program at Case Comprehensive Cancer Center.

In this exclusive interview at ASCO 2026, Prof. Barata shared his reflections on this year's congress, highlighting the most significant advances and breakthroughs compared to prior editions. He introduced the mechanism of action of 177Lu-rosopatamab tetraxetan, a novel radioligand therapy, and presented key findings from Part 1 of the global Phase III ProstACT study, with a focus on safety and dosimetry outcomes. He also offered his perspective on the future role of targeted radioligand therapies in metastatic castration-resistant prostate cancer (mCRPC), discussing open questions around efficacy endpoints, patient selection, and whole-course management.

0
0
Loading